AJAmir Ali Judaki

Amir Ali Judaki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Amir Ali Judaki has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Noninvasive Biomarkers for Early Detection of Primary Sclerosing Cholangitis in Ulcerative Colitis

    by Pedram Asadi Sarabi, Alireza Beheshti-Maal, Amir Ali Judaki, Seyedeh Kiana Teymoorian, Zohreh Hashemian, Elham Rismani, Asma Gul, Reza Malekzadeh, Moustapha Hassan, Massoud Vosough

    Primary sclerosing cholangitis (PSC) is a progressive cholestatic liver disease strongly associated with ulcerative colitis (UC). Although uncommon, PSC‐associated ulcerative colitis (PSCUC) represents a distinct subtype of inflammatory bowel diseases characterized by a higher risk of colorectal and hepatobiliary cancers. Early diagnosis remains a challenging issue because of the lack of specific biomarkers. Bioinformatic analysis of Gene Expression Omnibus (GEO) datasets identified potential, specific, and noninvasive biomarkers via differential gene expression and functional enrichment. After processing the data, S100A8 and S100A12 were identified as candidate biomarkers for detecting PSC in patients with UC. S100A8 encodes one component of calprotectin, the S100A8/S100A9 heterodimer widely used as a marker of intestinal inflammation. These two genes are primarily involved in inflammation, immune responses, and leukocyte recruitment, making them potentially useful biomarkers for early detection in PSC in UC patients. These biomarkers offer potential implications for disease stratification and therapeutic targeting. Further validation in prospective clinical studies is warranted to confirm their diagnostic and prognostic utilities.

  • Open Access

    Extracellular Matrix–Associated Biomarkers for Hepatocellular Carcinoma: Insights From Machine Learning and Single‐Cell Analysis

    by Pedram Asadi Sarabi, Elham Rismani, Amir Ali Judaki, Amirhossein Farrokhzad, Zahra Hendi, Moustapha Hassan, Massoud Vosough

    The 5‐year overall survival rate for hepatocellular carcinoma (HCC) patients remains below 20%. Alterations in the extracellular matrix (ECM) are increasingly recognized as central drivers of HCC initiation and progression. This study applied a system biology framework integrating omics data and machine learning to analyze gene expression and regulatory networks in HCC using The Cancer Genome Atlas. Eight ECM‐associated genes ( CSPG4 , CD34 , C1orf35 , ESM1 , MAPT , PLXDC1 , STC2 , and THBS4 ) were identified as upregulated diagnostic biomarkers with strong discriminatory power. Among them, MAPT , PLXDC1 , and STC2 showed significant associations with poor overall survival, defining a prognostic subset. Validation in the GSE104310 and GSE144269 datasets confirmed consistent expression patterns across cohorts. Functional enrichment linked these genes to tissue remodeling and angiogenesis. Single‐cell RNA sequencing revealed MAPT upregulation in T cells, PLXDC1 enrichment in cancer‐associated fibroblasts, and mild STC2 elevation in tumor‐associated macrophages and endothelial cells. These findings identify key ECM‐based biomarkers with potential for early detection, prognosis, and therapeutic targeting in HCC.